Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Methamphetamine | 7 | 2021 | 22 | 2.010 |
Why?
|
| Dopamine Agonists | 3 | 2020 | 15 | 1.400 |
Why?
|
| Dopamine | 3 | 2020 | 82 | 1.340 |
Why?
|
| HIV-1 | 6 | 2022 | 235 | 1.090 |
Why?
|
| Parkinson Disease | 3 | 2021 | 671 | 0.940 |
Why?
|
| HIV Infections | 5 | 2022 | 477 | 0.840 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2020 | 11 | 0.770 |
Why?
|
| Impulsive Behavior | 3 | 2018 | 15 | 0.750 |
Why?
|
| Rats | 14 | 2022 | 660 | 0.730 |
Why?
|
| Mianserin | 3 | 2017 | 8 | 0.680 |
Why?
|
| Animals | 17 | 2022 | 3681 | 0.670 |
Why?
|
| Behavior, Addictive | 1 | 2020 | 9 | 0.660 |
Why?
|
| Colon | 2 | 2018 | 124 | 0.650 |
Why?
|
| Choice Behavior | 2 | 2017 | 45 | 0.640 |
Why?
|
| Analgesics, Opioid | 4 | 2019 | 230 | 0.620 |
Why?
|
| Neurosciences | 1 | 2019 | 9 | 0.620 |
Why?
|
| Compulsive Behavior | 1 | 2018 | 1 | 0.610 |
Why?
|
| Reward | 3 | 2018 | 23 | 0.600 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 61 | 0.560 |
Why?
|
| Ketanserin | 1 | 2017 | 1 | 0.550 |
Why?
|
| Reinforcement Schedule | 1 | 2017 | 1 | 0.550 |
Why?
|
| Gambling | 1 | 2017 | 8 | 0.540 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 316 | 0.470 |
Why?
|
| Decision Making | 1 | 2017 | 220 | 0.460 |
Why?
|
| Behavior, Animal | 4 | 2021 | 50 | 0.430 |
Why?
|
| Self Administration | 4 | 2021 | 17 | 0.370 |
Why?
|
| Central Nervous System Stimulants | 3 | 2021 | 41 | 0.350 |
Why?
|
| Cocaine-Related Disorders | 2 | 2022 | 13 | 0.310 |
Why?
|
| Cocaine | 2 | 2022 | 31 | 0.310 |
Why?
|
| Rats, Transgenic | 4 | 2022 | 19 | 0.270 |
Why?
|
| Motor Activity | 4 | 2021 | 321 | 0.250 |
Why?
|
| Morphine | 3 | 2013 | 72 | 0.220 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 2 | 2015 | 12 | 0.210 |
Why?
|
| Self Stimulation | 3 | 2017 | 8 | 0.200 |
Why?
|
| Cerebral Cortex | 2 | 2015 | 154 | 0.190 |
Why?
|
| Corpus Striatum | 3 | 2022 | 65 | 0.190 |
Why?
|
| alpha-Synuclein | 2 | 2021 | 130 | 0.190 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2017 | 328 | 0.190 |
Why?
|
| Mitochondria | 1 | 2021 | 66 | 0.190 |
Why?
|
| Rats, Inbred F344 | 2 | 2018 | 35 | 0.180 |
Why?
|
| Male | 11 | 2022 | 14887 | 0.180 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2020 | 1 | 0.170 |
Why?
|
| Substantia Nigra | 1 | 2021 | 120 | 0.170 |
Why?
|
| Brain | 2 | 2021 | 1648 | 0.150 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2018 | 5 | 0.150 |
Why?
|
| Neuronal Plasticity | 1 | 2018 | 48 | 0.140 |
Why?
|
| Dopaminergic Neurons | 1 | 2018 | 49 | 0.140 |
Why?
|
| Myenteric Plexus | 1 | 2017 | 4 | 0.140 |
Why?
|
| Pain Management | 1 | 2019 | 143 | 0.140 |
Why?
|
| Conditioning, Operant | 2 | 2017 | 3 | 0.130 |
Why?
|
| Genotype | 1 | 2018 | 344 | 0.130 |
Why?
|
| Benzothiazoles | 1 | 2016 | 3 | 0.130 |
Why?
|
| Globus Pallidus | 2 | 2013 | 10 | 0.130 |
Why?
|
| Intestinal Mucosa | 1 | 2018 | 176 | 0.120 |
Why?
|
| Risk-Taking | 1 | 2016 | 34 | 0.120 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 314 | 0.120 |
Why?
|
| Synaptic Transmission | 1 | 2015 | 25 | 0.120 |
Why?
|
| Humans | 4 | 2022 | 27307 | 0.120 |
Why?
|
| Neurocognitive Disorders | 1 | 2015 | 13 | 0.110 |
Why?
|
| Receptors, AMPA | 1 | 2013 | 7 | 0.100 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2013 | 13 | 0.100 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2013 | 1 | 0.100 |
Why?
|
| Brain Chemistry | 1 | 2013 | 45 | 0.100 |
Why?
|
| Hyperkinesis | 1 | 2013 | 8 | 0.100 |
Why?
|
| Adolescent | 1 | 2019 | 2185 | 0.100 |
Why?
|
| Parkinsonian Disorders | 1 | 2016 | 225 | 0.100 |
Why?
|
| United States | 1 | 2019 | 2078 | 0.100 |
Why?
|
| Morphine Dependence | 1 | 2012 | 1 | 0.100 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2012 | 28 | 0.100 |
Why?
|
| Calcium Channels, L-Type | 1 | 2012 | 51 | 0.100 |
Why?
|
| Nucleus Accumbens | 2 | 2018 | 13 | 0.060 |
Why?
|
| Immunity | 1 | 2022 | 16 | 0.050 |
Why?
|
| Rotenone | 1 | 2021 | 9 | 0.050 |
Why?
|
| Locomotion | 1 | 2021 | 24 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2022 | 71 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 606 | 0.040 |
Why?
|
| Inflammation | 1 | 2022 | 287 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 2020 | 38 | 0.040 |
Why?
|
| Basal Forebrain | 1 | 2018 | 1 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2018 | 4 | 0.040 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2018 | 6 | 0.040 |
Why?
|
| eIF-2 Kinase | 1 | 2018 | 5 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2018 | 13 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 275 | 0.040 |
Why?
|
| Time Factors | 1 | 2021 | 1444 | 0.040 |
Why?
|
| Motivation | 1 | 2018 | 90 | 0.040 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 2017 | 2 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 28 | 0.030 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2017 | 52 | 0.030 |
Why?
|
| Oxidopamine | 1 | 2016 | 10 | 0.030 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2016 | 15 | 0.030 |
Why?
|
| Antiparkinson Agents | 1 | 2016 | 42 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 123 | 0.030 |
Why?
|
| Delay Discounting | 1 | 2016 | 24 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 331 | 0.030 |
Why?
|
| Hypothalamus | 1 | 2015 | 13 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 2015 | 50 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 561 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2013 | 1 | 0.030 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 1 | 2013 | 10 | 0.030 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2013 | 34 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2013 | 6 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2013 | 153 | 0.030 |
Why?
|
| Cues | 1 | 2012 | 38 | 0.020 |
Why?
|
| Prefrontal Cortex | 1 | 2013 | 136 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 375 | 0.020 |
Why?
|